BioCentury
ARTICLE | Strategy

Alexion executes

How Alexion's Synageva acquisition fulfills goals of 2011 strategy

May 18, 2015 7:00 AM UTC

The proposed acquisition of Synageva BioPharma Corp. is Alexion Pharmaceuticals Inc.'s biggest move to date under a four-year-old plan to diversify its portfolio.

The plan, announced in 2011, includes expanding Soliris eculizumab beyond paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), building a translational research organization and acquiring assets for additional rare and severe disorders...